Doug Sills

Doug Sills is a seasoned professional in corporate development and investment, currently serving as General Partner at Anthem Venture Partners since January 2018 and as Vice President of Corporate Development & Co-Founder at ImmunoVec since January 2020. Previously, Doug held the position of Vice President of Corporate Development at Celenex Therapeutics before its acquisition by Amicus Therapeutics and worked as an Associate at Moonshots Capital, along with various roles at CVS Health, including Senior Analyst and Senior IT Project Manager. Doug began a career in finance at Genpact Headstrong Capital Markets and has held several financial analyst roles across different organizations, including prITegic and MDT Holdings. Doug obtained a Bachelor of Science in Finance from the Indiana University - Kelley School of Business in 2012.